Across TCGA pan-cancer cohorts, FAM217B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated FAM217B data layer compared with 28 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FAM217B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM217B expression acts as an unfavorable survival marker.
LUAD, COAD, and LUSC are the cancer types where FAM217B Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.